Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

mosquitoes in Arturo's labThis project is in collaboration with:

Oxford University Clinical Research Unit in Vietnam, OUCRU: Professor Cameron Simmons, NDM, University of Oxford

Universidade Federal de Minas Gerais: Dr Flávio Guimarães da Fonseca, Microbiology Department, ICB - UFMG, Brasil

Benemérita Universidad Autónoma de Puebla: Dr Rosa Rocha Gracia and Dr Miguel Garcia Knight, Research Center in Microbiological Sciences, Sciences Institute, BUAP, México

Universidad Michoacana de San Nicolás de Hidalgo: Professor Martha Eva Viveros Sandoval, Head of Laboratorio de Hemostasia y Biología Vascular, “Dr. Ignacio Chávez” School of Medicine, UMNSH, México

Laboratorio Estatal de Salud Pública, Michoacán (LESP): MSP Gloria Alicia Figueroa Aguilar, Head of Public Health State Laboratory of Michoacán and MSP Wendy Vianey Padilla Cabrera, Coordinator of Epidemiology of the Public Health State Laboratory, Michoacán, México

Dengue is a re-emerging infectious disease of major global importance, representing an enormous burden for health care systems in endemic countries. A huge challenge in vaccine development is to design effective vaccines against variable pathogens, such as dengue virus (DENV). Pathogen variability means they are able to induce changes in their structure overtime allowing them to be more diverse and efficient. Dengue disease, transmitted by mosquitoes, can be caused by any of four different DENV serotypes. Exposure and infection with one serotype confers immunity against that specific serotype but not to the other three remaining serotypes. Moreover, studies have shown patients that previously suffered from dengue are in high risk to develop a more aggressive form of the disease if they come into contact with a different DENV serotype; a process known as Antibody-Dependent Enhancement (ADE). The aim of this project is to develop a universal vaccine able to induce protective immunity against all DENV serotypes. To this end, our team will develop methodologies to elicit immune responses against the most conserved viral epitopes and proteins, through the use of viral-vectored and VLP immunisation.

This project is supported by IDAMS-FP7, Oxford Martin School, MRC Confidence in Concept